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BACKGROUND 
Over the last years, life expectancy has significantly increased although multiple diseases 
persist with aging as a risk factor. In fact, despite the improvement in treatments, many 
elderlies suffer from cardiovascular diseases(1).  The pathophysiological changes of the aging 
heart include left ventricular (LV) hypertrophy, diastolic and systolic dysfunction, increased 
fibrosis and reduced inotropic reserve(2-4). These changes make aged heart more vulnerable 
to stress, leading to a high prevalence of cardiac diseases such as arrhythmias, coronary artery 
disease, myocardial infarction and heart failure (HF) (1, 5).  All these alterations are mirrored 
in animal models used in aging studies. In particular, the application of genetically modified 
mice to aging research has identified numerous critical molecular mechanisms involved in 
cardiac aging such as altered adrenergic signaling, mitochondrial dysfunction, increased 
cardiomyocyte apoptosis and oxidative stress(2, 6, 7). β-arrestin-1 (βarr-1) and βarr-2 proteins 
belong to the arrestin family and are ubiquitously expressed. They have been originally 
discovered as regulators of the G protein–coupled receptor (GPCR) signaling but both are 
now well known to be also G protein–independent signal transducers and interact with many 
proteins and protein kinases both in vitro and in vivo(8, 9). In the cardiomyocytes, when β-
adrenergic receptors (β-ARs) are stimulated by catecholamines, the G protein-coupled 
receptor kinase 2 (GRK2) phosphorylates β-ARs that then become targets for the binding of 
β-arrs. This β-arr binding prevents β-ARs further coupling to the G protein, reduces the level 
of functional receptors and induces their internalization where they go on to be degraded or 
resensitized before recycling to the membrane(10).  It is well established that GRK2 is 
upregulated in failing heart leading to β-AR dysfunctional signaling(10).  
Differently, cardiac membrane GRK2 levels are not altered with aging and the main 
mechanism involved in the age–related β-AR down-regulation/desensitization in 
cardiomyocytes remains still unknown(11).  Interestingly, β-arr-2 protein levels are increased 
in the aged heart(12).  However it is not clear so far if β-arr-2 plays a role in the decreased 
adrenergic signaling during cardiac aging. Thus, in the present study we have tested the 
effects of β-arrestin-2 deletion in a murine model of aging on cardiac function and age-related 
β-AR dysfunction. 
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METHODS 
Experimental animals 
All animal procedures were performed in accordance with the guidelines of the Institutional 
Animal Care and Use Committee of Temple University School of Medicine. Genetically 
engineered, β-arr2 KO (on C57BL/6 background) and corresponding C57BL/6 wild type 
(WT) male mice were used for this study, as previously published(13). All animals were bred 
and maintained on a C57Bl/6 background. Mice were studied for a 15-24-month-long period 
according to different experiments. 
 
Two-Dimensional Echocardiography and Strain Analysis 
Transthoracic echocardiography has been used to assess cardiac structure and function using a 
VisualSonics VeVo 2100 system (VisualSonics, Toronto, Ontario, Canada), as described. 
Mice were anesthetized in a specific isoflurane sedation box (induction 3.0% and 
maintenance 1–3%). Mice were next shaved to remove hair from the ventral thorax (from the 
neckline to mid-chest level). Then, mice were placed in a supine position on a heated table 
with embedded ECG leads. During echocardiography, anesthesia was maintained throughout 
the procedure with 1–3% isoflurane. Images were acquired in the short-axis B-mode and M-
mode for LV diameters, anterior and posterior wall measurements, and subsequently ejection 
fractional (EF) with a 18–38 MHz probe(14, 15). 
Long-axis B-mode images were recorded for endocardial longitudinal and radial strain as well 
as longitudinal strain rate (SR) and radial SR analysis using the Vevo Strain software 
following, as published(14, 16).  Strain, which evaluates change in length relative to the initial 
length (Strain = Final Length [L]/ Initial Length [L0]) was calculated either in the radial (from 
the center of the ventricle cavity outward) or longitudinal axis (from the apex to the base). 
The rate of change in strain (Strain Rate = Strain/Time) was also measured(14). Average and 
regional (6 segments: anterior basal zone, anterior middle zone, anterior apex, posterior basal 
zone, posterior middle zone, posterior apex) LV endocardial longitudinal and radial strain/SR 
were evaluated(16, 17). After echocardiograms were recorded, image series were randomly 
ordered and renumbered. All images were analyzed under their coded numbers in a blinded 
fashion, then the code was broken and animal data was sorted by treatment group then 
analyzed. 
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Membrane Preparation and Radioligand Binding 
β-AR density was measured in isolated cardiac plasma membranes using 125I-CYP 
(Iodocyanopindolol), as described(18). Membrane preparations from LV samples were 
prepared by homogenization in ice-cold lysis buffer (25 mM Tris, pH 7.4, 5 mM EDTA, 1 
µg/mL aprotinin, 1 µg/mL leupeptin) and centrifuged at 1,000 × g for 5 min at 4 °C. The 
supernatant was centrifuged at 30,000 × g, and the crude membrane pellet was resuspended in 
lysis buffer containing 10% glycerol and stored at −80 °C until use. The density of βAR on 
membranes was determined by saturation binding experiments. Membrane preparations (25 
µg of protein) were incubated with [125I]cyanopindolol ([125I]CYP; 200 pM; PerkinElmer) in 
binding buffer (75 mM Tris, pH 7.4, 2 mM EDTA, 12.5 mM MgCl2, 1 µg/mL aprotinin, 1 
µg/mL leupeptin). Incubations were performed in the presence or absence of propranolol (10 
µM) to determine nonspecific binding. The reactions were performed in a 250-µL volume and 
allowed to equilibrate at 37 °C for 1 h before filtering the membranes through a glass fiber 
filter (Whatman GF/C; Brandel). Each filter was washed five times with 5 mL of ice-cold 
wash buffer (10 mM Tris, pH 7.4, 10 mM EDTA) to remove unbound drug. The amount of 
total and non-specific radiolabel bound to cell membranes was determined on a gamma 
counter. All assays were performed in triplicate. Receptor density was normalized to 
milligrams of membrane protein. 
 
Western blot analysis 
Western blotting has been performed as published(15). LV samples (0.1 mg) were lysed in a 
RIPA buffer with protease (cOmplete-Roche, Indianapolis, IN, USA) and phosphatase 
inhibitors (PhosSTOP-Roche, Indianapolis, IN, USA) cocktail. Protein content was quantified 
with the Bio-Rad BCA protein assay (Bio-Rad Laboratories, Richmond, California, USA). 
Protein samples were separated by 4–20% SDS–polyacrylamide gel electrophoresis (Thermo 
Fisher Scientific) and then transferred to nitrocellulose membrane (Bio-Rad Laboratories). 
After blocking with a specific blocking buffer (Odyssey, LI-COR, Lincoln, Nebraska, USA), 
the membranes were incubated and probed with the first antibody at 4 °C overnight according 
to manufacturer’s instructions. Then, the proteins were stained with a corresponding Alexa 
Fluor 680- (1:5,000; Thermo Fisher Scientific) or IRDye 800CW-coupled (1:5,000; Rockland 
Inc. Limerick, PA, USA) secondary antibody, followed by visualization of the proteins with a 
LI-COR infrared imager (Odyssey), and quantitative densitometric analysis was performed 
applying Odyssey version 1.2 infrared imaging software. Protein levels of: β-arr2 (Santa Cruz 
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sc-13140; 1:1,000); NOX4 (Epitomics #3187-1; 1:1,000), Mn-SOD (BD-Biosciences 
#611580; 1:1,000) were assessed. 
 
Real-time PCR and RT-PCR 
Total RNA was isolated from LV specimens with TRIzol (Thermo Fisher Scientific) 
according to the company’s instructions. After RNA isolation, cDNA was synthesized by 
reverse transcription of the RNA (iScript cDNA synthesis kit, Bio-Rad Laboratories). Real-
time PCR was performed in triplicates on a CFX96 real-time PCR detection system (Bio-Rad 
Laboratories) using the SYBR Green mix (Bio-Rad Laboratories) and specific primers for 
mouse β-arr1 as follows: forward 5’-AAGGGACACGAGTGTTCAAGA-3’; reverse 5’-
CCCGCTTTCCCAGGTAGAC-3’; 
β-arr2 as follows: forward 5’-GGCAAGCGCGACTTTGTA-3’; reverse 5’-
GTGAGGGTCACGAACACTTTC-3’(19). The expression levels were normalized to the 
rRNA 18S. Specificity of PCR products was confirmed by melting curve and gel 
electrophoresis(15).  
Conventional RT-PCR for the presence of β-arr2 transcript in mRNA extracted from LV 
samples was performed with specific primers for mouse β-arr2 as follows: forward 5’-
AAGTCGAGCCCTAACTGCAA-3’; reverse 5’-TTCCGGTCCTTCAAGTAGTCA-3’ 
 
RESULTS 
β-arr2 mRNA expression and protein levels in aging hearts 
To confirm that aging is associated with increased β-arr2 in the heart(12),  we measured LV 
β-arr2 protein levels in young and old mice. There was a 2.7 fold increase in β-arr2 protein 
levels in 15- versus 6-month-old WT-mice (p<0.0001) (Fig. 1B). Differently, we found 
similar mRNA expression of β-arr2 in samples from 15- versus 6-month-old mouse hearts 
(Fig. 1A). 
 
β-arr2 deletion did not affect neither β-arr1 cardiac expression nor age-related cardiac 
hypertrophy  
In order to investigate the impact on cardiac aging of the genetic deletion exclusively of β-
arr2, we utilized the available global β-arr2 KO mouse model (Figure 2A). These mice breed 
normally and did not present any basal altered cardiovascular phenotype(13). β-arr2 KO-Old 
mice did not show different β-arr1 expression when compared to WT-Old mice (Figure 2B). 
As expected, aging in WT mice was associated with increase in body weight (BW) (6- vs 24 
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month-old: 23±0.65 vs 33±0.87), heart weight (HW) (6- vs 24 month-old: 0.12±0.0032 vs 
0.17±0.0036), and HW to tibia length ratio (HW/TL) (6- vs 24 month-old: 7±0.19 vs 
9.3±0.18) (Figure 3, Table). Interestingly, when compared to WT-Old mice, β-arr2-KO Old 
mice did not show any changes in BW (33±0.87 vs 32±0.79), HW (0.17±0.0036 vs 
0.18±0.0063), HW/BW (5.2±0.18 vs 5.5±0.2), HW/TL (9.3±0.18 vs 9.5±0.34) (Figure 3, 
Table). β-arr2 deletion did not affect BW, HW, HW/BW or HW/TL in young (6-month-old) 
mice, as well (Figure 3, Table). 
 
β-arr2KO deletion improves cardiac function during aging 
There were no differences between groups (β-arr2 vs. WT) in any of the echocardiographic 
measures (standard echocardiography) when mice were 6-month-old (Figure 4 and Table). 
Aging was associated with a decline in LV EF (6-month-old:  57±1.3; 20-month-old: 49±1.3) 
as well as increased LV internal   end-diastolic diameter (LVIDd) (6-month-old:  4.1±0.054; 
20-month-old: 4.5±0.066), LV internal   end-systolic diameter (LVIDs) (6-month-old:  
3.0±0.053; 20-month-old: 3.5±0.067), and LV mass of the anterior wall  (LV Mass AW) (6-
month-old:  114±3.9; 20-month-old: 136±6) (Figure 4 and Table).  
β-arr2KO deletion in old mice resulted in blunted age-related cardiac dysfunction.  In fact, β-
arr2KO 20-month-old mice, when compared to WT 20-month-old mice, showed increased EF 
(49±1.3 vs 57±1.8; p<0.01) as well as reduced LVIDd (4.5±0.066 vs 4.2±0.067; p<0.01) and 
LVIDs (3.5±0.067 vs 3.1±0.11; p<0.01)  (Figure4 and Table). No difference was found in LV 
mass AW between the Old groups (β-arr2KO-Old vs WT-Old: 136±6 vs 136±9.7). 
Strain analysis was performed on long-axis B-mode images to check longitudinal and radial 
strain parameters. When young, β-arr2KO and WT mice demonstrated similar average 
longitudinal and radial strain as well as average longitudinal SR and radial SR (Figure 5 A, C, 
E, G). Average Radial strain and radial SR were reduced while average longitudinal strain and 
longitudinal SR were not affected during aging in WT mice (Figure 5). Significant 
improvements in both average radial strain and radial SR were observed in β-arr2-KO Old 
when compared to WT-Old mice (p<0.05) (Figure 5B, D, F, H) 
In addition, β-arr2 deletion improved regional radial and radial SR in the anterior basal zone 
and posterior apex during aging (p<0.05) (Figure 6 B, D). No differences were found in 
average and regional longitudinal strain and longitudinal SR between β-arr2-KO Old and WT-
Old mice (Figure 5 B, D and Figure 7 B, D) 
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β-arr2KO deletion restored age-influenced cardiac β-AR density 
In an effort to explore the molecular mechanisms underlying the effect of the absence of β-
arr2 on cardiac function during aging, we also investigated β-AR density in β-arr2 and WT 
mice both when young and old. Consistent with the functional data, total β-AR density in the 
aged WT (24-month-old) hearts was reduced compared to WT young (6-month-old) hearts 
(WT-Young vs WT-Old: 79±2 vs 62±6.8 fmol/mg protein) (Figure 8). Importantly, β-arr2 
deletion restored age-dependent β-AR downregulation (p<0.05) (WT-Old vs β-arr2-Old: 
62±6.8 vs 84±7.2) (Figure 8). No difference was found between young groups in term of  
cardiac β-AR density (Figure 8). 
 
β-arr2KO deletion reduced age-determined Nox4 upregulation 
We confirmed that cardiac Nox4 is upregulated during aging(20)  (increase of 3.7 fold in WT-
Old compared to WT-Young; *p<0.001) and discovered that MnSOD is unchanged and 
probably is not able to metabolize enough ROS produced determining increased oxidative 
stress. (Figure 9 A, B). Intriguingly, we found that Nox4 was significantly down-regulated in 
βarr-1 KO- and βarr-2 KO-Old mice compared to WT-Old mice (respectively 40% and 30% 
decrease vs WT-Old; respectively p<0.0001 and p<0.01 vs WT-Old) while Mn-SOD values 
were similar in cardiac samples from old groups. 
 
DISCUSSION 
In the present study, we have demonstrated that βarr-2 deletion in aged mice is able to: a) 
improve age-related cardiac dysfunction b) enhance average and regional cardiac radial strain 
as well as radial SR during in aging heart c) restore age-related cardiac β-AR desensitization   
d) reduce cardiac oxidative stress.  
Cardiovascular diseases impose a huge social, economical and clinical burden worldwide. 
The aging of the population in combination with increased survival in patients with coronary 
artery disease, hypertension, diabetes and arrhythmias has led to a tremendous growth in both 
the prevalence and incidence of HF(1, 21). Therefore, there is an enormous need to invest in 
treatments contributing to a successful aging and increasing the quality of life.  A lot of 
investments and efforts have been spent in the last decades in order to counteract the 
development and progression of cardiovascular diseases. Considerable advances in 
pharmacological treatment of HF have been achieved but researchers have not been focusing 
enough on cardiac age-related alterations (22). This is crucial since a frail heart is more prone 
to develop cardiac dysfunction after stress (myocardial infarction, hypertension, diabetes, 
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etc.).  Unfortunately, the basic mechanisms that cause the aging of the heart are still poorly 
understood. Age-related cardiac modifications are represented by cardiomyocyte hypertrophy, 
increased myocardial thickness and cardiac fibrosis, which together affect LV structure and 
function(2). Many studies have shown that the aging is characterized by changes of β-AR 
system such as increased plasma catecholamine levels, reduction of cardiac receptor density 
and their internalization as well as decreased adenylyl cyclase activity and cAMP 
production(6, 12, 23).  Cardiac β-AR dysfunction during aging leads to reduced exercise 
tolerance, decreased LV inotropic reserve and less susceptibility to β-blockade compared to 
young people(6). Although changes in β-AR agonist responsiveness in the failing and aging 
heart are quite similar, GRKs expression and activity seem to be unaltered during aging(24, 
25). Hence, the main molecular mechanism involved in β-AR dysfunction during aging is still 
undetermined. Interestingly, Dobson et al. studied potential molecular mechanisms of reduced 
β-AR signaling in the aged heart and found β-arr2 to be upregulated despite β-arr2 is known 
to be less expressed compared to β-arr1 in the heart(12, 26). In addition, a recent study 
elucidated the phosphorylation site of the β1-AR at Ser461/Ser462 in the distal part of the C-
terminus to determine β-arr2 recruitment and receptor internalization(27).  
Previous studies have demonstrated a role for β-arr1 and β-arr2 during myocardial ischemia. 
β-arr1 KO mice show improved cardiac function in a model of post–myocardial infarction 
HF. At this regard, the underlying mechanisms were referred to improved cardiac β-AR 
signaling and function due to cardiac β-Arr1 absence and, decreased circulating levels of 
cathecolamines and aldosterone due to adrenal β-Arr1 deletion(28). β-arr-2 KO mice have 
greater mortality compared to WT mice after MI and their infiltrated macrophages induce 
huge cardiac inflammation(29). Moreover, β-arr2 overexpression stimulate cardiac 
contractility and reduced LV dilation after MI via sarco[endo]plasmic reticulum Ca2+-
ATPase (SERCA2a) increased activity(30). However, it is not been shown whether β-arr2 
plays a role in age-dependent cardiac β-AR desensitization and functional decline.  
Our study is the first indicating that β-arr2 deletion is able to induce a significant increase in 
cardiac function, as indicated by the significant improvement in LV EF and blunted age-
related LV dilation observed in β-arr2 KO-Old compared to WT-Old (20-month-old) mice 
(Fig. 4 and Table). Importantly, the β-arr2 KO and WT mice showed similar cardiac 
parameters when young (6-month-old) (Fig.4 and Table).  No difference was found in HW, 
HW/BW, HW/TL or LV Mass AW (Fig. 3-4; Table) suggesting that β-arr2 is not involved in 
hypertrophic response during aging. 
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Recently, echocardiographic speckle-Tracking based strain imaging has emerged as an 
accurate non-invasive tool for the evaluation of LV function and morphology in mouse 
models, beyond the standard measurements(16, 31). It has been shown that echocardiographic 
strain analysis is a valuable and reproducible technique both in elderly patients and mouse 
models of cardiac aging(31-33). Interestingly, we found that that β-arr2 deletion was able to 
counteract the decrease in radial strain parameters during aging. In fact, β-arr2 KO-Old mice 
showed increased both average radial strain and average radial SR when compared to WT-Old 
mice (Fig.5). In addition, differently from WT-Old mice, β-arr2 KO-Old mice preserved 
radial strain and radial SR in the anterior basal zone and posterior apex. No differences were 
found in terms of longitudinal strain or longitudinal SR between β-arr2 KO and WT mice 
both at 6- and 20-months time-point.  
Interestingly, we found β-arr2 protein levels to be upregulated in aging heart while we did not 
find a difference in β-arr2 mRNA expression levels between in LV lysates from WT-Young 
and WT-Old mice (Fig. 1).  Probably, β-arr2 transcript and protein expression decoupling is 
due to age-related post-translational regulations. At this regard, it is well known a decrease in 
total rates of protein degradation with age and β-arr ubiquitination has been shown to be 
regulated by different proteins such as parkin and Mdm2(34, 35).   
In addition, our results indicate that β-arr2 deletion is not counterbalanced by β-arr1 
upregulation in aged hearts.  This is crucial since β-arrs have structural analogies and share 
several functions in GPCR regulation and GPCR-independent transduction signaling(36).  
In order to check the molecular mechanism involved, we have measured cardiac β-AR density 
in β-arr2 KO and WT mice when young and old. β-AR altered responsiveness and signaling 
are recognized to be a relevant pathogenic mechanism for reduced LV function during aging 
in animal models and in humans(6). However, therapeutic interventions able to restore age-
related cardiac β-AR abnormalities has not been found, yet. Our results showed that β-arr2 
deletion was able to completely restore β-AR down-regulation with β-AR levels similar to 
those observed in young mice. Tang et al. confirmed the importance of β-AR pathway during 
aging and showed that the activation of cardiac Adenylyl Cyclase 6 expression, effector 
molecule for β-AR signaling, improved aging-related LV systolic and diastolic function 
through enhanced sarcoplasmic reticulum calcium uptake(23). 
In our study, βarr-2 deletion induced results similar to those reported by Tang et colleagues, 
improving aging-impaired LV contractile function (Fig. 3-7). However, βarr-2 deletion should 
have more beneficial effect due to its multiple roles: 1) βarrs not only bind to GRK 
phosphorylated receptors to induce receptor internalization but also act as a scaffold protein 
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for numerous other molecules such as phosphodiesterase to further diminish β-AR-induced 
cAMP signal(37-39); 2) βarr-2 is involved in heterologous desensitization of βARs by other 
GPCR stimuli (such as dopamine or angiotensin II) which block β-adrenergic-induced protein 
kinase A phosphorylation of phospholamban and myocyte contractility. 
This latter finding is particularly relevant taking into consideration the age-dependent increase 
of local renin-angiotensin system in the myocardium(40).  
We believe that the different effects of β-arr-2 deletion during cardiac aging and post-
ischemic HF are due to different cells and molecular mechanism involved. In fact, 
macrophage β-arr-2 plays a protective role in MI-induced inflammation while during aging β-
arr-2 seems to be a crucial modulator of β-AR function in cardiomyocytes (Fig. 8)(29).   
With age, the heart shows a decrease in the number of cardiomyocytes, increase in their size 
and in fibrotic areas. All these phenomena are related to the production of ROS during aging, 
which are considered to be of mitochondrial origin(41). Nox4 is a key enzyme in ROS 
production while Mn-SOD shows an anti-oxidant role(20). It has been demonstrated that 
Nox4 is upregulated during aging especially in the mitochondria and its overexpression 
induces cellular senescence in fibroblasts and apoptosis in cardiomyocytes(20).  Intriguingly, 
Philip et al. have recently demonstrated that β-arrs are upregulated in cardiac fibroblasts from 
failing hearts and regulate mitochondrial superoxide production via Nox4(42). Our results 
show that β-arr2 is involved in age-dependent Nox-4 upregulation suggesting that reduced 
oxidative stress could improve, at least in part, cardiac function and remodeling in β-arr2 KO-
Old compared to WT-Old mice (Fig. 9). Although additional studies will be required to 
determine whether global deletion of β-arr2 is beneficial for cardiac aging due to β-arr2 role 
in cardiomyocytes or in other cardiac cell populations, our current data suggest a therapeutic 
potential for β-arr2 inhibition in aging hearts. 
 
CONCLUSIONS 
In summary, the present study reports that β-arr2 deletion reverses age-related cardiac 
dysfunction and LV dilatation. Importantly, the beneficial effects of β-arr2 deletion were 
found in global and regional radial strain parameters. As a contributing mechanism, improved 
LV function is associated with restored β-AR density and reduced oxidative stress in aged 
hearts. 
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Figure 3: 
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Figure 8: 
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FIGURE LEGENDS 
Figure 1: Aging is associated with increased β-Arrestin 2 protein levels: 
A:  Quantification of RT-PCR data showing β-Arrestin 2 mRNA levels of left ventricular 
(LV) samples from WT-Young (3 months old) and WT-Old (15 months old) mice. 
Quantitation normalized with 18s as control and expressed as fold of WT-Young.  
B: Representative Western blotting (top) and densitometric quantitation (bottom) in LV 
samples from WT-Young and WT-Old mice for β-Arrestin 2 . Representative blot shown 
includes GAPDH as loading control. Densitometric quantitation, normalized with GAPDH as 
control and expressed as fold of WT-Young.  n= 4 to 5 per group. *, p<0.0001 vs WT-Young. 
T-test was used between groups. 
 
Figure 2: β-Arrestin 2 deletion does not significantly alter β-Arrestin 1 expression 
during aging: 
A: PCR in cardiac mRNA isolated from β-Arrestin 2 KO or WT mice for confirmation of the 
absence of β-Arrestin2 transcript. 18s used as control. B: Quantification of RT-PCR data 
showing β-Arrestin1 mRNA levels of left ventricular (LV) samples from WT-Old (15 months 
old) and  β-Arrestin 2 KO-Old mice. Quantitation normalized with 18s as control and 
expressed as fold of WT-Old. n= 4 per group. T-test was used between groups. 
 
Figure 3: β-Arrestin 2 deletion does not affect cardiac hypertrophy during aging:  
Heart weight (HW) (A), HW/body weight (HW/BW) (B) and HW/tibia length (HW/TL) (C) 
in WT and  β-Arrestin 2 KO (β-Arr2KO) mice. Both mice have been studied when 3- 
(Young) and 24- (Old) -month-old. n= 6 to 26 per group. T-test was used between groups. 
 
Figure 4: β-Arrestin 2 deletion ameliorates age-related cardiac dysfunction:  
Ejection fraction (EF) (A, B), left ventricular internal diameter at diastole (LVIDd) (C, D) and 
left ventricular mass of the anterior wall (LV Mass AW) (E, F) as measured by standard 
echocardiography in WT and β-Arrestin 2 KO (Barr2KO) mice. Both mice have been studied 
when 6- and 20-month-old (6-mo and 20-mo). n= 6 to 19 per group. **p<0.01 vs WT-20mo. 
T-test was used between groups. 
 
Figure 5: β-Arrestin 2 deletion counteracts age-related radial strain dysfunction:  
Average longitudinal strain (A, B), longitudinal strain rate (SR) (C, D), radial strain (E, F) 
and radial SR (G-H) as measured by echocardiographic speckle-tracking based strain imaging 
in WT and β-Arrestin 2 KO (Barr2KO) mice. Both mice have been studied when 6- and 20-
month-old (6-mo and 20-mo). n= 6 to 18 per group. *p<0.05 vs WT-20 mo. T-test was used 
between groups. 
 
Figure 6: β-Arrestin 2 deletion improves segmental radial strain during aging:  
Radial strain (A, B) and radial strain rate (C, D) for 6 different segments of left ventricle 
(anterior basal zone, anterior middle zone, anterior apex, posterior apex, posterior middle 
zone and posterior basal zone) as measured by echocardiographic speckle-tracking based 
strain imaging in WT and β-Arrestin 2 KO (Barr2KO) mice. Both mice have been studied 
when 6- and 20-month-old.  n= 6 to 18 per group. *p<0.05. T-test was used between groups. 
 
Figure 7: β-Arrestin 2 deletion does not affect segmental longitudinal strain during 
aging:  
Longitudinal strain (A, B) and longitudinal strain rate (C, D) for 6 different segments of left 
ventricle (anterior basal zone, anterior middle zone, anterior apex, posterior apex, posterior 
middle zone and posterior basal zone) as measured by echocardiographic speckle-tracking 
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based strain imaging in WT and β-Arrestin 2 KO (Barr2KO) mice. Both mice have been 
studied when 6- and 20-month-old. n= 6 to 18 per group. T-test was used between groups. 
 
 
Figure 8: β-Arrestin 2 deletion ameliorates age-related β-adrenergic receptor 
dysfunction: 
β-adrenergic receptor (βAR) density (femtomoles of receptor per milligram of protein) in WT 
and  β-Arrestin 2 KO (β-Arr2KO) mice. Both mice have been studied when 3- (Young) and 
24- (old) month-old. n= 6 to 9 per group. *p<0.05. T-test was used between groups. 
 
Figure 9: β-Arrestin 1 or 2 deletion ameliorate oxidative stress during aging: 
Representative Western blotting (top) and densitometric quantitation (bottom) in left ventricle 
(LV) samples from WT-Young (3 months old) and WT-Old (15 months old) mice for 
NADPH oxidase 4 (NOX4) (A) and Manganese-dependent superoxide dismutase (MnSOD) 
(B). Representative Western blotting and densitometric quantitation in LV samples from WT-
, β-Arrestin 1KO (β-Arr1 KO)- and β-Arr2 KO- Old mice(15-month-old) for NOX4 (C) and 
MnSOD (D). Densitometric quantitation, normalized with GAPDH as control and expressed 
as fold of WT-Young or WT-Old, as appropriate. n = 4 to 5 per group. *p<0.001 vs WT-
Young. **p<0.0001 vs WT-Old; #p<0.01 vs WT-Old. T-test or One-way ANOVA and Tukey 
test were used between groups, as appropriate. 
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TABLE	  
 6-month-old mice 20-month-old mice 
 WT β-Arr 2 KO p-value WT β-Arr 2 KO p-value 
BW (g) 23±0.65 23±0.66 NS 33±0.87 32±0.79 NS 
HW (g) 0.12±0.0032 0.12±0.0054 NS 0.17±0.003
6 
0.18±0.0063 NS 
HW/BW (mg/g) 5.4±0.11 5.4±0.14 NS 5.2±0.18 5.5±0.2 NS 
HW/TL 
(mg/mm) 
7±0.19 7.1±0.28 NS 9.3±0.18 9.5±0.34 NS 
HR (bpm) 492±8 462±13 NS 494±13 480±14 NS 
EF (%) 57±1.3 57±2.7 NS 49±1.3 57±1.8** <0.01 
LVIDd (mm) 4.1±0.054 4.1±0.13 NS 4.5±0.066 4.2±0.067** <0.01 
LVIDs (mm) 3.0±0.053 3.0±0.15 NS 3.5±0.067 3.1±0.11** <0.01 
LVAWd (mm) 0.79±0.033 0.82±0.059 NS 0.76±0.029 0.89±0.052* <0.05 
LVAWs (mm) 1±0.037 1.1±0.063 NS 1.1±0.029 1.2±0.028 NS 
LVPWd (mm) 0.72±0.02 0.7±0.022 NS 0.77±0.031 0.81±0.047 NS 
LVPWs (mm) 0.98±0.035 1±0.043 NS 0.91±0.052 1.1±0.035* <0.05 
LV Mass AW 114±3.9 113±5.3 NS 136±6 136±9.7 NS 
 
Table legend: Physical parameters and echocardiography measurements: 
Body weight (BW), heart weight (HW), HW/BW, HW/tibia length (HW/TL), heart rate (HR), 
ejection fraction (EF), left ventricular internal  diameter at diastole (LVIDd) and systole 
(LVIDs), anterior wall in diastole (LVAWd) and  systole (LVAWs), posterior wall in diastole 
(LVPWd) and systole (LVPWs), and mass of the anterior wall  (LV Mass AW) were 
evaluated in WT and β-Arrestin 2 KO (β-Arr2KO) mice. Both mice have been studied when 
6- and 20-month-old.  Values represent mean±SE. n=6 to 26 per group. *p<0.05 vs WT-20-
month-old **p<0.01 vs WT-20-month-old. T-test was used between groups. 
 
 
 
